1. Kasuga, Yusuke, Ouda, Ryota, Watanabe, Masashi, Hatakeyama, Shigetsugu, Kobayashi, Koichi S. 2023. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA. In Proceedings of the National Academy of Sciences of the United States of America, 120, e2218955120. doi:10.1073/pnas.2218955120. https://pubmed.ncbi.nlm.nih.gov/37279268/
2. Huang, Hong, Lu, Jianrong, Aukhil, Ikramuddin, Pirih, Flavia, Chang, Jia. 2023. FBXO11 regulates bone development. In Bone, 170, 116709. doi:10.1016/j.bone.2023.116709. https://pubmed.ncbi.nlm.nih.gov/36863499/
3. Zhang, Hao, Xia, Peng, Yang, Zhangshuo, Zhang, Zhonglin, Yuan, Yufeng. . Cullin-associated and neddylation-dissociated 1 regulate reprogramming of lipid metabolism through SKP1-Cullin-1-F-boxFBXO11 -mediated heterogeneous nuclear ribonucleoprotein A2/B1 ubiquitination and promote hepatocellular carcinoma. In Clinical and translational medicine, 13, e1443. doi:10.1002/ctm2.1443. https://pubmed.ncbi.nlm.nih.gov/37837399/
4. Chan, Kah Lok, Gomez, Juliana, Cardinez, Chelisa, Burr, Marian L, Dawson, Mark A. 2022. Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. In Cancer cell, 40, 1190-1206.e9. doi:10.1016/j.ccell.2022.09.007. https://pubmed.ncbi.nlm.nih.gov/36179686/
5. Schneider, Christof, Kon, Ning, Amadori, Letizia, Basso, Katia, Dalla-Favera, Riccardo. 2016. FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease. In Blood, 128, 660-6. doi:10.1182/blood-2015-11-684357. https://pubmed.ncbi.nlm.nih.gov/27166359/
6. Gregor, Anne, Meerbrei, Tanja, Gerstner, Thorsten, Sticht, Heinrich, Zweier, Christiane. . De novo missense variants in FBXO11 alter its protein expression and subcellular localization. In Human molecular genetics, 31, 440-454. doi:10.1093/hmg/ddab265. https://pubmed.ncbi.nlm.nih.gov/34505148/
智鼠故事 
